PGLYRP3/PGRPIA Antibody (187C434)

Western Blot: PGLYRP3/PGRPIA Antibody (187C434) [NB100-56729]

Western Blot: PGLYRP3/PGRPIA Antibody (187C434) [NB100-56729] - Analysis in cell lysates from human brain using this antibody at a dilution of 1:500.

Immunocytochemistry/ Immunofluorescence: PGLYRP3/PGRPIA Antibody (187C434) [NB100-56729]

Immunocytochemistry/Immunofluorescence: PGLYRP3/PGRPIA Antibody (187C434) [NB100-56729] - A. HCECs were exposed to HKCA (106 cells/ml) with prior incubation in the absence or presence of isotype IgG (10ug/ml), dectin-1 neutralizing Ab (10ug/ml), BAY11-7082 (10uM) or NF-kB activation inhibitor quinazoline (NF-kB-I, 10uM) for 1 h. HCECs were treated with 106 cells/ml HKCA for 48 hours in 8-chamber slides and examined by immunofluorescent staining for PGLYRPs 3 and 4. (NB100-56721) C. The percentages of positive cells of PGLYRPs 3 and 4 staining in HCECs in A was quantified. Results shown are the mean +/- SD of four independent experiments; *** p<0.001, as compared with normal control; ^^ p<0.005, ^^^ p<0.001, as compared with HCECs exposed to HKCA. Magnification: 400x (bar = 25um). Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0128039) licensed under a CC-BY license.

Immunohistochemistry: PGLYRP3/PGRPIA Antibody (187C434) [NB100-56729] -

NF-kappaB p65 activation was induced by HKCA and inhibited by dectin-1 neutralizing antibody and NF-kappaB activation inhibitor quinazoline (NF-kappaB-I) in HCECs.A). HCECs were exposed to HKCA (106 cells/ml) with prior incubation in the absence or presence of isotype IgG (10ug/ml), dectin-1 neutralizing Ab (10ug/ml), BAY11-7082 (10uM) or NF-kappaB activation inhibitor quinazoline (NF-kappaB-I, 10uM) for 1 h. HCECs were treated with 106 cells/ml HKCA for 48 hours in 8-chamber slides and examined by immunofluorescent staining for PGLYRPs 2-4. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26039076), licensed under a CC-BY licence.